Výsledky vyhledávání - "Monomethyl auristatin F"

Akademický článek

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Autor: Asim V. Farooq, Simona Degli Esposti, Rakesh Popat, Praneetha Thulasi, Sagar Lonial, Ajay K. Nooka, Andrzej Jakubowiak, Douglas Sborov, Brian E. Zaugg, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Joanna Opalinska, January Baron, Trisha Piontek, Julie Byrne, Ira Gupta, Kathryn Colby

Publikováno v: Ophthalmology and Therapy, Vol 9, Iss 4, Pp 889-911 (2020)

Abstract Introduction Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody–drug conjugate (ADC; or immunoconjugate) that delivers a cy

Externí odkaz: https://doaj.org/article/c9f8e5b32350407bb7943466355dff73

Zobrazit plný text záznamu

Plný text ve formátu HTML

Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy

Autor: Jiawei Li, Fan Fei, Qinqin Cheng, Jianming Xie, Stan G. Louie, Hua Pei, Junji Watanabe, Yong Zhang, Alireza Abdolvahabi, Zhefu Dai, Tianling Hou, Xiao-Nan Zhang, Goar Smbatyan, Heinz-Josef Lenz

Publikováno v: Journal of Controlled Release. 336:433-442

Random conjugations of chemotherapeutics to monoclonal antibodies result in heterogeneous antibody-drug conjugates (ADCs) with suboptimal pharmacological properties. We recently developed a new technology for facile generation of homogeneous ADCs by

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37e33306f65a791d6f8497768fce6789
https://doi.org/10.1016/j.jconrel.2021.06.041

Zobrazit plný text záznamu

Halogenation at the Phenylalanine Residue of Monomethyl Auristatin F Leads to a Favorable cis/trans Equilibrium and Retained Cytotoxicity

Autor: Mirkka Sarparanta, Surachet Imlimthan, Iris Katariina Sokka, Filip S. Ekholm, Mikael P. Johansson, Hannu Maaheimo

Publikováno v: Sokka, I K, Imlimthan, S, Sarparanta, M, Maaheimo, H, Johansson, M P & Ekholm, F S 2021, ' Halogenation at the phenylalanine residue of monomethyl auristatin f leads to a favorable cis/ trans equilibrium and retained cytotoxicity ', Molecular Pharmaceutics, vol. 18, no. 8, pp. 3125-3131 . https://doi.org/10.1021/acs.molpharmaceut.1c00342
Molecular Pharmaceutics

Halogenation can be utilized for the purposes of labeling and molecular imaging, providing a means to, e.g., follow drug distribution in an organism through positron emission tomography (PET) or study the molecular recognition events unfolding by nuc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95f58ef077c9074a6334b247722d50d
https://doi.org/10.1021/acs.molpharmaceut.1c00342

Zobrazit plný text záznamu

A new immunochemical strategy for triple-negative breast cancer therapy

Autor: Chih-Wei Lin, Richard A. Lerner, Alex R. Nanna, Christoph Rader, Geramie Grande, Tianqing Zheng

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports

Triple-negative breast cancer (TNBC) is a highly diverse group of malignant neoplasms which tend to have poor outcomes, and the development of new targets and strategies to treat these cancers is sorely needed. Antibody–drug conjugate (ADC) therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfaa02ca4ccf9bad5a6056cffff70c5a
https://doaj.org/article/65dfaed7185b4b46a02f81c93c98f21c

Zobrazit plný text záznamu

Plný text ve formátu HTML

Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma

Autor: Kazuhiro Hanazaki, Minoru Fujimoto, Tsuyoshi Takahashi, Ichiro Murakami, Tetsuji Naka, Keiichiro Yokota, Takashi Matsunaga, Hidetoshi Eguchi, Keisuke Toya, Shigehiro Tsujii, Shogo Kobayashi, Sunao Uemura, Satoshi Serada, Yuichiro Doki, Tsutomu Namikawa

Publikováno v: Molecular Cancer Therapeutics. 20:1713-1722

Cholangiocarcinoma is a highly malignant cancer. Many patients need systemic chemotherapy to prevent tumor development and recurrence; however, their prognosis is poor due to the lack of effective therapy. Therefore, a new treatment option is urgentl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2726273e9d4f71e172f52641c12696dd
https://doi.org/10.1158/1535-7163.mct-21-0015

Zobrazit plný text záznamu

EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma

Autor: Francesco Pignatti, Kyriaki Tzogani, Lucía Lopez Anglada, Johanna Lähteenvuo, Carolina Prieto, Harald Enzmann, Karri Penttilä, Blanca Garcia-Ochoa, Tuomo Lapveteläinen, Christian Gisselbrecht, Julio Delgado

Publikováno v: Oncologist

On August 25, 2020, a marketing authorization valid through the European Union was issued for belantamab mafodotin monotherapy for the treatment of multiple myeloma (MM) in adult patients who have received at least four prior therapies, whose disease

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fb53c9d316e99987a0eaa785466117c
https://doi.org/10.1002/onco.13592

Zobrazit plný text záznamu

Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate

Autor: Anatol Oleksijew, Thomas John, Diana Cao, Mark Anderson, Joann P. Palma, Kedar S. Vaidya, Puey-Ling Chia, Michael J. Mitten, Hugh D. Falls, Hui K Gan, Edward B. Reilly, Andrew M. Scott, Wenqing Gao, Erwin R. Boghaert

Publikováno v: Molecular Cancer Therapeutics. 19:2117-2125

ABBV-321 (serclutamab talirine), a next-generation EGFR-targeted antibody–drug conjugate (ADC) incorporates a potent pyrrolobenzodiazepine (PBD) dimer toxin conjugated to the EGFR-targeting ABT-806 affinity-matured AM1 antibody. ABBV-321 follows th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71074b9a7cd4b37b7bea94b938e74e7d
https://doi.org/10.1158/1535-7163.mct-20-0149

Zobrazit plný text záznamu

Belantamab Mafodotin: First Approval

Autor: Anthony Markham

Publikováno v: Drugs. 80:1607-1613

Belantamab mafodotin (BLENREP™; belantamab mafodotin-blmf) is a first-in-class monoclonal antibody-drug conjugate (ADC) that has been developed for the treatment of multiple myeloma by GlaxoSmithKline. The ADC comprises an antibody targeting B-cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e163713aa13511db852fdac6b4357d25
https://doi.org/10.1007/s40265-020-01404-x

Zobrazit plný text záznamu

Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability

Autor: Stephen R. Adams, Donald P. Pizzo, Ezra E.W. Cohen, Seung M. Song, Dina V. Hingorani, Joseph A. Aguilera, Sunil J. Advani, Maria F. Camargo, Matthew K. Doan, Andrew M. Lowy, Daniel J. Scanderbeg

Publikováno v: Mol Cancer Ther
Molecular cancer therapeutics, vol 19, iss 1

The most successful therapeutic strategies for locally advanced cancers continue to combine decades-old classical radiosensitizing chemotherapies with radiotherapy. Molecular targeted radiosensitizers offer the potential to improve the therapeutic ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb9b4640c0fb7564c174fa18d056e28e
https://doi.org/10.1158/1535-7163.mct-18-1302

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání